IMPORTANCE Early esophagogastric cancer (OGC) stage presents with nonspecific symptoms.
I n the United Kingdom, upper gastrointestinal symptoms account for at least 3% of consultations in primary care. 1 The national esophagogastric cancer (OGC) audit reported 7044 cases of OGC diagnosed in 2016. Many patients present with advanced-stage disease and only 38% of cases can be treated with a curative intent. 2 Current UK referral guidelines for suspected OGC focus on alarm symptoms such as dysphagia and odynophagia, despite these symptoms having poor sensitivity and specificity for OGC and often only occur in advanced disease translating into a poor outcome and overall survival. 3 There is a wide range in the rate of oesophagogastro duodenoscopy (OGD) among general practice populations in England and OGC patients belonging to practices with the lowest rates of OGD referral are at greatest risk of poor overall survival owing to advanced tumor stage at diagnosis. 4 Furthermore, OGD is an expensive invasive investigation, with poor uptake in specific ethic minority populations consequently affecting survival. 5 This high prevalence of upper gastrointestinal symptoms coupled with the low incidence of OGC and the nonspecific nature of symptoms in early disease highlight the need for a triage test to direct patients to have OGD.
Volatile organic compounds (VOCs) emitted from the human body have been of interest to researchers for several decades, 6 with associations previously suggested between specific VOCs and breath and lung, bladder, and breast cancers. [7] [8] [9] We analyzed exhaled breath samples using selected ion flowtube mass spectrometry (SIFT-MS) from 210 patients, 81 with OGC and 129 control patients. A diagnostic model of 13 VOCs was able to diagnose OGC with a sensitivity of 89% and speci-ficityof94%. 10 Several phase 1 biomarker studies linking noninvasively measured VOCs to the presence of cancer similar to our own have been published, 7-9,11-13 with very few attempts to externally validate these findings in a further prospective cohort of patients from several centers.
The objective of this multicenter validation study was to establish the diagnostic accuracy of a previously identified set of breath VOCs dysregulated with the presence of OGC in a multicenter setting.
Methods
Multivariable logistic regression model (stepwise regression) (eMethods 1 in the Supplement) was used to create a 5-VOCs model which were butyric acid, pentanoic acid, hexanoic acid, butanal, and decanal from our previously published data set. 10 The predictive probabilities generated by this 5-VOC diagnostic model were then used to generate an receiver operating characteristic (ROC) curve, which showed a good diagnostic accuracy with an area under the curve of 0.90 (SD, 0.02).
Based on 50% of patients in the study population having cancer (1 patient with a benign abnormality was recruited to 1 patient with cancer) and maintaining a sensitivity and specificity of 80% for the diagnostic model derived from our previous research, the sample size estimated for the multicenter external validation study was 325 patients; 162 patients with esophageal or gastric cancer and 163 patients with benign conditions or a normal upper gastrointestinal tract.
Breath samples were taken from 3 hospitals (St Mary's Hospital Imperial College London, University College London Hospital, and The Royal Marsden Hospital) and transported to St Mary's VOC laboratory for SIFT-MS analysis. The National Health Service (NHS) Health Research Authority (NRES Committee London-Camden and Islington) approved the study, and written informed consent was obtained.
The full protocol for this study was previously published. 14 The study was reported according to STARD 2015 (Standards for Reporting of Diagnostic Accuracy Studies) guidelines (eMethods 2 in the Supplement). 15 The trial was registered with the National Health Service, Health Research Authority Patients 18 years or older with upper gastrointestinal symptoms attending for endoscopy or surgery were eligible. In the cancer cohort only patients with histologically confirmed nonmetastatic esophagogastric adenocarcinoma (stage I-III) were included. All patients in the cancer cohort were sampled when they were neoadjuvant naive.
Patients who had a documented active infection, were unable to provide informed consent, or unable to provide a 500-mL breath sample were excluded. Patients with Barrett esophagus were excluded from the control group (this is a premalignant condition worthy of independent investigation).
Breath Sampling Methodology
After informed consent was obtained from all patients, we followed the sampling protocol used in our previous clinical studies, 10 which was informed by our investigations on the influence of breath maneuvers and hospital environment on VOC measurements. 16, 17 Patients fasted for a minimum of 4 hours prior to their breath sample collection. Patients rested in the same area for at least 20 minutes prior to exhaled breath collection and all samples were obtained immediately prior to endoscopy or surgery. Patients were asked to perform a single deep nasal inhalation followed by complete exhalation via their mouth into secure 500-mL steel breath bag (GastroCHECK) via a 1-mL Luer lok syringe (Terumo Europe, Leuven, Belgium). Patients in the cancer and control groups were recruited consecutively. The research team were aware of clinical diagnosis when breath sampling the patients, however the clinical team performing the OGD or surgery were blind to the results of the breath analysis.
For each VOC measurement, the syringe plunger was removed from the 1-mL Luer lok syringe and the steel breath bag was directly connected via the syringe barrel to the sample inlet arm of the SIFT-MS instrument. For the multi-ion monitoring mode, selective VOCs from breath were analyzed for a total of 60 seconds and measured concentrations were averaged over this time for each VOC.
SIFT-MS permits online, real-time VOC quantification. 18,19 It has been used in the study of VOCs in breath and urine from patients with conditions including cystic fibrosis and bladder cancer. 20,21 The SIFT-MS instrument allows real-time detection and quantification of VOCs in biological samples such as exhaled breath without sample preparation. 22 We have previously confirmed the reproducibility of VOCs measurements using SIFT-MS. 23 A panel of 30 VOCs including the 5 VOCs forming our diagnostic model were analyzed for each breath sample, as previously described. 10
Clinical Data
A detailed medical proforma was completed by the consenting clinician or research fellow using information provided by the patient as well as clinical investigations. These data included patient demographics, tumor characteristics, comorbidities, medications, and lifestyle measures. Diagnostic endoscopy and/or operative findings were recorded for each patient.
Histopathologic examination of tissues obtained via endoscopy or from surgically resected specimens was carried out. The reference test was considered positive on OGC histopathologic diagnosis.
SIFT-MS instrument was calibrated daily to 6% water in human exhaled breath. All breath samples were tested using SIFT-MS to ensure that percentage water from the exhaled breath sample in the bag was between 5% and 7%. If this was not the case the sample was discarded because it was likely to be unreliable and representative of bag malfunction. All samples were analyzed within 4 hours of collection. Our methodological studies demonstrated the stability of trace VOCs up to 48 hours from the time of patient sampling when using the GastroCHECK steel breath bag (eMethods 3 in the Supplement). Weekly samples were taken from the ambient room air at the participating hospitals where patients were being breath sampled and also from the laboratory air from where samples were analyzed. This was to ensure that there was no contamination from the ambient room air causing anomalous results, which could represent an important confounding factor (eMethods 4 in the Supplement). Breath sampling methodology was standardized. We performed human factors analysis, which demonstrated several potential sources of error in breath sampling that can affect the results of the analysis. Therefore, all clinicians and researchers participating in this study underwent a thorough credentialing process involving observation of consent, performing breath sampling, and storage of samples prior to participating in the study (eMethods 5 in the Supplement). Threshold of detection of SIFT-MS analysis was defined as 1 part per billion by volume (ppbv), based on previously performed statistical modeling (eMethods 6 in the Supplement).
To confirm the identified VOCs obtained in the exhaled breath using SIFT-MS; we conducted cross-platform validation with Gas chromatography mass spectrometry ([GC-MS] considered the gold standard for compound identification owing to the use of chromatographic separation). Exhaled breath was collected using the same method from 20 patients. The VOC content from each GastroCHECK bag was transferred using an air-sampling pocket pump (SKC 210-1002 series) at 50 mL/ min onto inert coated stainless steel Tenax/Carbograph-5TD sorbent tubes (Markes International Ltd, Llantrisant) prior to GC-MS analysis (eMethods 7 in the Supplement).
Statistical Analysis
Comparison of predicted cancer risk and actual OGD findings or histology from endoscopic biopsies (reference standard test) was then made, and the overall diagnostic accuracy (sensitivity, specificity, and ROC analysis) for this noninvasive diagnostic investigation was determined. A similar ROC analysis was performed based on predicted cancer risk from clinical parameters defined by National Institute for Health and Care Excellence (NICE) criteria. 3 Potential confounding factors across the study groups were evaluated by employing the Kruskal-Wallis test for continuous variables and χ 2 test for discrete variables. Linear regression models were used to assess any influence of patient demographic factors, or medications, on VOC concentrations measured. P < .05 was used to assign statistical significance. All statistical analysis was performed using the statistical software SPSS (version 22, IBM).
Results
Only 1 invited patient declined to participate in the study with a patient acceptability rate of 99.7% to undertake and complete the test. No adverse events were observed during breath sampling.
Patient Demographics and Tumor Factors
After necessary exclusions owing to sample quality, defined as inadequate percentage of water (n = 20), 335 patients in total were included; 172 patients in the control group and 163 patients with esophageal or gastric cancer. In the control group, 89 (51.7%) patients had a normal upper gastrointestinal tract on endoscopy or only the presence of a hiatal hernia. The most common diagnoses among the remaining participants in the control group were esophagitis, gastritis, or duodenitis with or without erosions in 59 (34.3%) patients, followed by the presence of benign gastric polyps in 12 (7.0%) patients and achalasia or esophageal stricture in 11 (6.4%) patients.
In the cancer group there were significant increases in patient age, proportion of male and white patients, ex-smokers, ASA grade 3, and hypertensive patients, with a reduced proportion of patients with liver impairment ( Table 1 ). There were also significant increases in the use of statin, β-blocker, and ACE-inhibitor medications in the cancer group (Table 1) . Dysphagia, vomiting, and gastrointestinal bleeding were increased, and abdominal pain reduced, as presenting symptoms in the cancer group (eMethods 8 in the Supplement). Furthermore, the breakdown of the cancer-specific factors including stage and tumor location is provided in Table 2 with 72 (44.2%) of tumors being gastric in origin, 123 (69.3%) being T3 or T4, and 106 (65%) being nodal positive.
Cross-Platform GC-MS Validation
In conjunction with SIFT-MS analysis, TD-GC-MS analysis was applied to breath from the same cohort of patients (n = 20) to cross-validate the identity of measured VOCs. eMethods 9 in the Supplement summarizes the VOC identification by GC-MS via mass spectrum (MS) matching of detected compounds to the commercial NIST library, as well as their calculated retention indices (RI) to those of authentic chemical standards undergone separation on the ZB-624 column. Overall, the presence of 30 VOCs was confirmed except for pentanol owing to its limited level of signal-to-noise ratio (SNR<5) among the analyzed samples.
SIFT-MS Analysis and VOC-Based OGC Diagnosis
The concentration of butyric acid, hexanoic acid, butanal, and decanal showed significant differences between the cancer and control groups (eMethods 10 in the Supplement). Five VOCs were then taken forward to form a risk-prediction model for the diagnosis of esophagogastric cancer, and included in a mul-tivariable logistic regression analysis with cancer diagnosis as the dependent variable (eMethods 10 in the Supplement). To ensure these factors were not associated with a confounding demographic variable or presenting symptom that differed between the comparison groups, linear regression models were performed for each of the 5 VOCs (eMethods 10 in the Supplement). There were no significant differences in the concentration of these 5 VOCs between patients with esophageal or gastric cancer (eMethods 10 in the Supplement).
The predictive probabilities generated by this 5-VOC diagnostic model were then used to generate an ROC curve, which showed a good diagnostic accuracy with an area under thecurveof0.85(SD,0.02)( Figure) . This translated to a sensitivity of 80% and specificity of 81% for the diagnosis of esophagogastric cancer. This compared with the diagnostic accuracy generated by a clinical parameters test based on NICE guidelines for endoscopy referral, 3 which had an area under the curve of 0.73 (SD, 0.03), sensitivity of 59%, and specificity of 81% (eMethods 11 in the Supplement). 
Discussion
This multicenter study demonstrated a sensitivity of 80% and specificity of 81% of a single breath test in the diagnosis of esophagogastric cancer, thus validating the 5-VOC breath model. All patients with cancer included in the study were receiving a curative treatment pathway, highlighting the potential value of the test in detecting operable disease and the potential impact on survival. The sensitivity of 80% compares favorably to the existing technologies such as fecal occult blood test (sensitivity ranging from 30%-70%) for colorectal cancer, 24 and more specifically to upper gastrointestinal disease, the cytosponge (sensitivity 73%) for Barrett esophagus. 25 An important finding with both these technologies was an increase in sensitivity associated with multiple episodes of testing, which could be an important area for further research of breath testing. At present the NICE guidance for endoscopy referral is based on age threshold and symptom criteria. Patients aged over 55 years with dyspepsia, or those of any age with alarmtype symptoms are considered eligible for direct referral for endoscopy and assessment of the upper gastrointestinal tract. 3 Despite these guidelines a huge degree of variability remains in referral patterns for endoscopy. 4 The breath test for esophagogastric cancer aims to provide clinicians with an objective assessment of need for endoscopic referral. Given the association of all 5 VOCs with esophagogastric cancer, this may in the future allow for calculation of stratified risk for individual patients, which would require an independent largescale study to fully validate. The consensus of key stakeholders in a decision workshop was to locate breath testing in primary care to triage patients with nonspecific symptoms to have endoscopy based on risk of OGC (eMethods 12 in Supplement 2). This view has been endorsed by our recent finding that the diagnostic model for OGC is different from that for colorectal cancer, 26 providing the concept for a single breath test for multiple gastrointestinal cancers. If a clinician is presented with a patient with gastrointestinal symptoms that do not prompt referral based on NICE criteria, he/she would not need to watch and wait to see if symptoms worsen but could offer the exhaled breath test immediately. The clinician would order a breath test in much the same way as routine blood tests. A nurse can perform the test and send breath samples to a regional laboratory for analysis. A positive result would warrant immediate referral for endoscopy. A negative test would permit the clinician to reassure the patient and offer retesting if symptoms persist. Because endoscopy is an expensive investigation, 1 with a low diagnostic yield of 2% to 5%, 2 a triage breath test prior to endoscopy could substantially reduce the number of negative endoscopies and increase the cancer yield making the diagnostic pathway more effective with improved patient experience. Avoiding unnecessary investigations would also free up resources in the NHS. Concerns regarding clinical application of breath sampling and transport have led to the development of thermal desorption tubes, which allow breath samples to be stored for up to 1.5 months and transported between sites. 27,28 These tubes can be used multiple times after cleaning and potentially for multiple diseases using the same analytical platform, which may serve to further lower the cost of a breath test.
The mechanism of production of these VOCs in the cancer state may involve changes at a genetic and cellular level causing metabolic alterations in enzymatic pathways. Aldehydes have generated much research interest given their link as a possible carcinogen and also their elevation in other types of cancers. 28 Genetic dysregulation of aldehyde metabolism is present in patients with esophageal cancer. 29,30 Lipid peroxidation flux may provide a link between inflammation, aldehydes, and cancer. 12,31 Gastric microbiome associated with cancer may also be a contributing factor to the production of VOCs, yet to be defined. 32, 33 Limitations There are limitations associated with this study that must be considered in the interpretation of the findings. Although demographic data were collected and regressed for in the analysis, there may have been other unmeasured confounding variables that could have influenced the changes in VOCs observed. Also, the reference standard test was histopathologically proven tissue diagnosis through endoscopy or from surgically resected specimen, although gastric and esophageal cancers can be missed in up to 8% of diagnostic endoscopies, 34,35 however endoscopy remains the best diagnostic test currently available. Furthermore, most patients presented in the current study have T3 esophagogastric cancer, in line with disease patterns in the UK. Therefore the diagnostic accuracy of the test to identify early stage (T1) cancer remains undetermined by the current study. It must be acknowledged that given a current sensitivity of 80% there is still potential for further refinement of exhaled breath test-ing and thereby improvements in cancer detection rates; a successful evolution observed in other triage investigations such as stool DNA testing for colorectal cancer. 36, 37 Further investigations are also needed to examine the sensitivity of breath analysis on multiple testing samples in patients who initially have a negative result.
Conclusion
This validation study showed a sensitivity of 80% and a specificity of 81% for the breath test to diagnose esophagogastric cancer. The next stage is a large-scale diagnostic accuracy study among the primary care population where the test is intended to be employed.
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eMethods 3: Optimisation of Bag materials
We conducted an experiment to optimise the bag materials to minimise losses of trace VOCs as part of a multi-centre investigation.
Liquid Calibration Unit (LCU)
The loading of the bags with known amounts of linear aliphatic aldehydes was carried out with the aid of a liquid calibration device (s-LCU from Ionicon Analytik, GmbH -Innsbruck, Austria). The calibration mixture was generated by injecting a mixture of aldehydes (propanal to heptanal, at 1·0-1·7 mg/L in water) at a flow of 50 ml/min into a heated (100°C) chamber. Upon injection, the liquid encountered a gas stream, flowing at 1,000 ml/min; this allowed for rapid evaporation of the analytes, due to the generation of micro-droplets. Knowing the starting concentration of the single aldehydes and supposing the evaporation of the liquid to be instantaneous and quantitative, this should generate C3-C7 linear aliphatic aldehydes in the lowparts-per billion volume (ppbv) range. This assumption was experimentally verified by connecting the LCU device to the SIFT-MS. C3-C6 aldehydes showed a good agreement between expected and measured values, with concentrations in the ±20% range with respect to theoretical values. In the case of heptanal, the measured concentration was repeatable, but considerably lower than the theoretical one. This was probably due to poor evaporation efficiency, also observed for higher boiling point aldehydes, which were evaluated in a preliminary experiment (C8 to C10). The relative humidity of the obtained calibration mixture was 6·2%, and therefore similar to that occurring in breath. The gas stream injection was achieved by means of pressurised gas (synthetic air, BOC gases -Guildford, UK), passed through a scrubber (Supelco -Bellefonte, PA) and connected to the LCU. The calibration mixture was conveyed to the SIFT-MS by means of a short (10 cm) section of PEEK tubing. For the multi-ion monitoring mode, selective VOCs (trace aldehydes) from breath were analysed for a total of 60s and measured concentrations were averaged over this time for each VOC. Bag materials under investigation were Nalophan (Kalle Ltd, Germany), Tedlar (Sigma Aldrich Ltd., Poole -UK), and Steel (Gastrocheck-Bag-XL-Bedfont Scientific Limited). Bags were stored at room temperature, and were sampled at 0, 24, 48, and 72 hours. Three bags were sampled at each time point with the median and range presented for analysis. Kruksall-Wallis test was utilised to compare the concentration of the trace VOCs at different time points, with a P value of 0.05 taken to indicate statistical significance. Comparison of the three bag types showed variable performance in the ability to retain water and trace aldehydes over the up to 72-hour study period. When stored in Nalophan for 72 hours, there were significant reductions in water (57·1%), propanal (40·4%), butanal (48·7%) and hexanal (55·2%). Tedlar performed well for most aldehydes, however again there were significant reductions in water (47·9%) and heptanal (54·7%). Steel performed well in the retention of most aldehydes with the exception of pentanal, which showed a 73·9% reduction during the 72-hour study period (eTable 5 and eFigure 3). 
eFigure 3: Illustrating losses over time of C3 -C7 aldehydes when stored in different bag materials
The results of this study demonstrate that there is loss of trace VOCs from breath bags that impair the interpretation of multi-centre breath studies that involve long periods of sample transport and storage. For the purpose of our investigation steel breath bags appear to have the best performance in reducing loss of trace aldehydes. However, the results of the study do highlight the need for minimising storage time and facilitating early SIFT-MS analysis. Therefore we amended our protocol in response to this study so that all breath samples were stored in steel breath bags and analysed within 8 hours of being taken from the patient.
eMethods 4: Effect of ambient room air upon analysis of trace VOCs
The primary objective of this study was to examine the variation in the levels of traces VOCs from the ambient air in different clinical environments where patients are commonly sampled. The secondary objective of this study was to evaluate the intra-and inter-day variability in the levels of VOCs in these four locations. Room air samples were collected in breath bags using a room air pump. Room air samples were on 5 separate days over a 1-month period in the morning and afternoon from 3 hospital environments (outpatient clinic, endoscopy and theatre waiting rooms) and the laboratory. For each VOC measurement, the syringe plunger was removed from the 1ml Luer lok syringe and the breath bag was directly connected via the syringe barrel to the sample inlet arm of the SIFT-MS instrument. For the multi-ion monitoring mode, selective VOCs from ambient air were analysed for a total of 60s and measured concentrations were averaged over this time for each VOC. The only significant variation in room air VOCs between rooms was seen for butenal, acrolein, butanol, pentanol, butyric acid, putreisceine, methanol33 and isoprene. Importantly there was no significant variation between hospital environments seen in all VOCs included in the oesophago-gastric cancer prediction model previously generated by Kumar et al [8] . Room air from different clinical environments has previously been shown to vary in terms of more abundant VOCs. The present study identifies minimal variation in trace VOCs associated with oesophago-gastric cancer from previous research. However good scientific practice will remain to sample ambient room air at the time of breath sampling to ensure, that exogenous contribution to the patient breath profile is minimal. Regular ambient room air sampling was therefore included as part of the protocol for all clinical samples taken as part of this research.
eMethods 5: Human factor analysis of breath bag sampling
Previous breath research has most commonly involved one or two well-trained researchers taking breath samples from individual patients. Single centre breath studies are of value in establishing pilot research findings, however require validation in larger scale multi-centre studies in order to demonstrate reproducibility of findings. This present study sought to utilise human factor analysis to identify potential sources of error in the breath sampling and analysis process that may lead to errors in sample study and spurious results. Clinicians and researchers undertaking breath sampling were directly observed or videoed during the first three times they performed breath sampling from patients using the 500mL Steel breath bag (Gastrocheck-Bag-XL-Bedfont Scientific Limited). Human factors and Ergonomic (HFE) analysis was employed to identify potential errors and the consequences of these errors associated with the breath sampling technique. HFE is a multidisciplinary science in which human behavior, capacities, and engineering principles are used to explore why errors occur, and how to reduce the likelihood or preventable harm to individuals, with the specific aim to support human performance and safety. The observation of 3 clinicians and 2 researchers during the first 3 episodes of breath sampling identified 10 tasks with associated errors and consequences associated with breath bag sampling. From this, a task analysis was developed ( Table S1 ) that allows assessment of researchers before permitting them to enroll patients in multicentre breath studies. This task analysis was taken forward and used in practice as part of the multi-centre trial to ensure all researchers were adequately trained to take breath samples, and reduced any previously demonstrated variability in performance of breath sampling. Correlation plot demonstrating a good correlation between methyl phenol measured on NO+ and H3O+, up a value of log 0 or 1ppbv. A previous study [1] depicts that volatile constituents consisting hydrophilic -OH or -COOH functional group tend to adhere to the non-polar column through Van der Waals forces and to each other, resulting lower vapour pressure and undesired chromatograph behaviour such as peak tailing. Non-polar column phase such as ZB-624 column exhibits less suitable for analysis of polar constituents. For a successful GC determination of underivatised free fatty acids, application of polar FFAP column phase would be preferred [2] .
Amongst all identified VOC, propanal was distinctly distinguished from the Ethylphenol is a phenolic compound produced in wine and beer by the spoilage yeast Dekkera bruxellensis [4] but its presence in breath is yet reported. 
Methods
Decision conferencing is a series of workshops attended by key players who are facilitated by an impartial specialist in decision theory and group processes, to resolve important issues of concern to the participants. The purposes of decision conferencing are to achieve in the group of key players a shared understanding of the issues, to create a sense of common purpose despite difference of opinion, and to achieve commitment to effective policy and to best practice guidelines. Decision conferencing has been developed over the past 28 years at the London School of Economics by Professor Larry Phillips and his colleagues, and is now used world-wide by hundreds of organisations in all sectors. It is an effective way to tackle difficult problems quickly and thoroughly, and it produces outputs that are readily understood by others because the process of arriving at recommendations is totally transparent.
In applying decision conferencing to this project, we did convene a panel of chairs of multidisciplinary oesophago-gastric teams, gastroenterologists, general practitioners, surgeons and patient members from the oesophageal patient association. The meeting explored the issues, informed participants regarding diagnostic accuracy and cost-effectiveness, and identified factors that affect uncertainty about the location of the test in patient pathway, discussed possible consequences and the key attributes of those consequences, and came to a decision.
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Results
On 22 January 2015, 18 people (including five patients) gathered at the Royal College of Surgeons to provide guidance for the developers of a breath test for oesophagogastric cancer that will ensure adequate patient uptake and provide early diagnosis.
Following introductions around the table, data were presented about oesophagogastric cancer, noting that the incidence of oesophageal adenocarcinoma in the UK is the highest in the world. It was explained that patients in the UK take too long to present to their GP, partly because symptoms of heartburn and indigestion are not widely recognised as potentially indicative of oesophago-gastric cancer. Endoscopy is the gold standard for diagnosis, but it is costly and invasive and experienced as a very unpleasant investigation by many patients.
Furthermore it was explained the status of the breath test approach, with data suggesting that the risk prediction model has a good sensitivity and specificity. We stated that the goals for implementing the breath test are, for patients, earlier diagnosis at an early stage of the disease, better survival, and more patient satisfaction, and, for the NHS, tailored referral and lower cost.
A demonstration of the breath test, using the currently-available technology and software, followed.
Questions were asked about the current status of the breath test, which led to an extended discussion and further questions and answers, as follows:
• Greater general awareness of the disease is needed, and will be stimulated by a programme in the last week of January 2015. If the result is more endoscopies, than that would help to support need for the breath test.
• The breath test would be a screening tool providing decision support for the GP, who would take account of other features as well.
• A positive breath test would typically result in the patient being referred for an endoscopy.
• More work is needed on contributing risk factors, such as co-morbidities.
• Pharmacies could alert patients with continuing heartburn. Awareness could be enhanced by pharmacists because they may communicate more amongst themselves than GPs.
• At this stage of development it is not clear if a simple, hand-held device is feasible or desirable.
• Some patients might be too alarmed at a positive finding, but there are soft answers when the breath test is positioned as a screening device, not a programme.
• The group agreed that GP surgeries are the first step in positioning the test.
Pharmacies would be second, but only if it would not be necessary (as now) to send off the breath sample to complete the test.
Discussion
The consensus reached through this process of decision conferencing was that at least initially, the breath test for oesophago-gastric cancer would be ideally situated in the primary care setting or general practitioners. The most commonly cited reason for this was that this is the point of primary referral for diagnostic endoscopy, and thus the breath test may be able to triage patients for endoscopy. The benefits identified by the majority of participants would be that the breath test would provide objective criteria that may support decision-making by GPs.
However
Markar SR et al JAMA Oncology workshop participants did also suggest that there is a portion of patients who fail to seek medical attention for long-standing symptoms of heartburn, and would typically self-medicate with medications purchased over the counter in a pharmacy.
Therefore a secondary position for the breath test may be in the pharmacy in order to reach this population of patients who typically would not seek medical attention.
A further important finding from this workshop was that the majority of participants were unsure as to the optimal patient interface for any breath test in the future. This is clearly needed to plan in the next stage of the breath test development as a robust breath test in clinical practice is unlikely to gain widespread dissemination using breath bags for sample collection. Sensor based technology may allow for the development of disease-specific hand-held devices capable of utilisation in the primary care setting. However participants in the workshop felt that delivery of the results of the test would be critical to reduce the psychological stress upon the patient and therefore a sensor based hand-held device would need to be performed by a trained medical professional capable of delivering the results of the test in a balanced manner. The alternative would be to utilise thermal desorption tubes for breath sample storage, and transport for analysis to a central laboratory [289] . A possible advantage of thermal desorption tubes would be the potential to allow breath profiling of a number of diseases and therefore the test could be more costeffective and utilised for multiple purposes.
Conclusions
• The ideal position of the breath test in the diagnostic pathway would initially be in the GP surgery and community pharmacy as a secondary location.
• The exact device for breath sampling as a hand-held device to allow for point-ofcare testing or thermal desorption tubes to allow for laboratory testing, remains undetermined by the present workshop.
